Extract from the Register of European Patents

EP About this file: EP4225366

EP4225366 - IMDQ-PEG-CHOL ADJUVANT AND USES THEREOF [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  14.07.2023
Database last updated on 10.03.2026
FormerThe international publication has been made
Status updated on  16.04.2022
Most recent event   Tooltip28.10.2025New entry: Renewal fee paid 
Applicant(s)For all designated states
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place
New York, NY 10029 / US
For all designated states
Universiteit Gent
Sint-Pietersnieuwstraat 25
9000 Gent / BE
[2024/21]
Former [2023/33]For all designated states
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place
New York, NY 10029 / US
For all designated states
Universiteit Gent
Sint-Pietersnieuwstraat 25
9000 Gent / BE
Inventor(s)01 / GARCIA-SASTRE, Adolfo
New York, NY 10029 / US
02 / SCHOTSAERT, Michael
New York, NY 10029 / US
03 / CHOI, Angela
New York, NY 10029 / US
04 / DE GEEST, Bruno
9000 Gent / BE
05 / DE VRIEZE, Jana
9000 Gent / BE
 [2023/33]
Representative(s)Studio Torta S.p.A.
Via Viotti, 9
10121 Torino / IT
[N/P]
Former [2023/33]Jones Day
Rechtsanwälte, Attorneys-at-Law, Patentanwälte
Prinzregentenstrasse 11
80538 München / DE
Application number, filing date21878555.807.10.2021
[2023/33]
WO2021US54024
Priority number, dateUS202063089442P08.10.2020         Original published format: US 202063089442 P
[2023/33]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2022076723
Date:14.04.2022
Language:EN
[2022/15]
Type: A1 Application with search report 
No.:EP4225366
Date:16.08.2023
Language:EN
The application published by WIPO in one of the EPO official languages on 14.04.2022 takes the place of the publication of the European patent application.
[2023/33]
Search report(s)International search report - published on:US14.04.2022
(Supplementary) European search report - dispatched on:EP04.10.2024
ClassificationIPC:A61K39/39, A61K47/60, A61K31/4745, A61K31/80, C07D471/04, C07J9/00
[2024/45]
CPC:
A61K47/60 (EP); C07D471/04 (EP,US); A61K39/12 (EP);
A61K39/215 (US); A61K39/39 (EP); A61K47/554 (EP);
A61P31/14 (EP,US); A61P31/16 (EP); C07J43/003 (EP);
A61K2039/543 (EP); A61K2039/555 (EP); A61K2039/55505 (EP);
A61K2039/55511 (US); A61K2039/57 (EP); A61K2039/575 (EP,US);
A61K2039/70 (EP); C12N2710/10343 (EP); C12N2760/16134 (EP);
C12N2770/20034 (EP); Y02A50/30 (EP) (-)
Former IPC [2023/33]A61K39/39, A61K47/60, A61K31/4745, A61K31/80
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2023/33]
TitleGerman:IMDQ-PEG-CHOL-ADJUVANS UND VERWENDUNGEN DAVON[2023/33]
English:IMDQ-PEG-CHOL ADJUVANT AND USES THEREOF[2023/33]
French:ADJUVANT IMDQ-PEG-CHOL ET UTILISATIONS ASSOCIÉES[2023/33]
Entry into regional phase22.03.2023National basic fee paid 
22.03.2023Search fee paid 
22.03.2023Designation fee(s) paid 
22.03.2023Examination fee paid 
Examination procedure22.03.2023Examination requested  [2023/33]
22.04.2025Date on which the examining division has become responsible
09.05.2025Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
08.07.2025Amendment by applicant (claims and/or description)
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
08.07.2025Request for further processing filed
08.07.2025Full payment received (date of receipt of payment)
Request granted
16.07.2025Decision despatched
Fees paidRenewal fee
27.10.2023Renewal fee patent year 03
28.10.2024Renewal fee patent year 04
27.10.2025Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]   JANA DE VRIEZE ET AL: "Potent Lymphatic Translocation and Spatial Control Over Innate Immune Activation by Polymer-Lipid Amphiphile Conjugates of Small-Molecule TLR7/8 Agonists", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, VERLAG CHEMIE, HOBOKEN, USA, vol. 58, no. 43, 12 September 2019 (2019-09-12), pages 15390 - 15395, XP072102682, ISSN: 1433-7851, DOI: 10.1002/ANIE.201905687 [A] 1-15 * Scheme 2; page 15390, column right, paragraph last - page 15391, column left, paragraph 2 * * figures 3,4C1 * * figure 4 *

DOI:   http://dx.doi.org/10.1002/anie.201905687
 [A]   HE ZHI-YAO ET AL: "Recent development of poly(ethylene glycol)-cholesterol conjugates as drug delivery systems", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, vol. 469, no. 1, 25 April 2014 (2014-04-25), pages 168 - 178, XP029029889, ISSN: 0378-5173, DOI: 10.1016/J.IJPHARM.2014.04.056 [A] 1-15 * paragraph [0004]; figure 4 *

DOI:   http://dx.doi.org/10.1016/j.ijpharm.2014.04.056
 [T]   JANGRA SONIA ET AL: "Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine**", ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 60, no. 17, 11 March 2021 (2021-03-11), Hoboken, USA, pages 9467 - 9473, XP055943944, ISSN: 1433-7851, Retrieved from the Internet DOI: 10.1002/anie.202015362 [T] * the whole document * * figures 1-5A *

DOI:   http://dx.doi.org/10.1002/anie.202015362
International search[A] WO2013166110  (UNIV YALE et al.) [A] 1-8, 12-20, 29-35, 58, 60- 63, 89-91; 93 * Sheet 4, Figure 4 *
 [A] US8946421  (JOHNSON DAVID A et al.) [A] 1-8, 12-20, 29-35, 58, 60-63, 89-91; 93 * Col 3, In 45-61; Col 4. In 10-31 *
 [A] US2018110874  (LI LIXIN et al.) [A] 1-8, 12-20, 29-35, 58, 60-63, 89-91; 93 * para [0119]; [0224]; pg. 21, Table 1 *
 [A]   HE ET AL.: "Recent Development of poly(ethylene glycol)-cholesterol conjugates as drug delivery systems", INTERNATIONAL JOURNAL OF PHARMACEUTICS, vol. 469, 2014, pages 168 - 178, XP029029889, DOI: 10.1016/j.ijpharm.2014.04.056 [A] 1-8, 12-20, 29-35, 58, 60-63, 89-91; 93 * . pg. 172, Figure 4 A *

DOI:   http://dx.doi.org/10.1016/j.ijpharm.2014.04.056
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.